Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 06, 2023

Impact of First-Cycle Neutropenia and Dose Reduction on the Outcomes in Patients With HR+/HER2− MBC Treated With First-Line Palbociclib and Hormonal Therapy

The Breast Journal


Additional Info

Disclosure statements are available on the authors' profiles:

The Breast Journal
Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome
Breast J 2023 Aug 25;[EPub Ahead of Print], KAEA Elnaghi, HA Alghanmi, SA Elsamany, et al

Further Reading